Drug Trial Radar · NCT05249634
Testosterone Treatment in Men With Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Mar 15, 2022
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- St. Louis UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Clarus Therapeutics, Inc.
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).
Conditions
- Hypogonadism, Male
- Kidney Disease, Chronic
Interventions
Jatenzo PillDrug
oral tablet daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Testosterone concentrationsTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Saint Louis Univeristy
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.